Study of Comparative Effectiveness of Prucalopride and Lubiprostone in Constipation Predominant Irritable Bowel Syndrome

• Status: Recruiting
• Trial end date: 2022-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This will be a semi-experimental study on constipation predominant IBS patient. One group of patient will receive prucalopride 2mg daily and another group of patient will receive lubiprostone 8 microgram twice daily. IBS-SSS and IBS-QOL score will be recorded at baseline and at follow up at 3 week and 6 week. Effectiveness of both drug will be evaluated by comparing the baseline data with data at 3 week and 6 week(IBS-SSS and IBS-QOL).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
• Treatments: Prucalopride

Criteria

Inclusion criteria:

• Meet Rome IV criteria for IBS-C

• Patients given informed written consent

Exclusion Criteria:

• Current treatment with laxative or SSRI

• Use of any medication indicated for treatment of IBS within preceding 2 weeks of enrollment

• Organic disorder of the large or small bowel (e.g. inflammatory bowel disease, tuberculosis, diverticular disease)

• Diagnosis of any medical condition associated with constipation except IBS-C (e.g DM, Hypothyroidism, CVD, parkinsonism)

• Clinical feature suggestive of organic disease (e.g. unexplained significant weight loss, rectal bleeding)

• Previous gastrointestinal or abdominal surgery (except for common causes unrelated to IBS)

• Abnormal laboratory tests (CBC, CRP, RBS, S. Creatinine, S.TSH, ECG)

• Mechanical obstruction

• Known severe depression, psychiatric disorder.

• Pregnancy or lactation